What Does Semaglutide 2.4 mg Actually Cost per Unit of Health Gained in Adolescents, and Is It Worth It?

At a glance

| Parameter | Detail | |---|---| | Trial | STEP-TEENS (NCT04102685) | | N | 201 adolescents (ages 12-17, BMI ≥95th percentile) | | Intervention | Semaglutide 2.4 mg subcutaneous once weekly + lifestyle intervention | | Comparator | Placebo + lifestyle intervention | | Duration | 68 weeks | | Primary endpoint | Percent change in BMI from baseline | | Key result | -16.1% BMI change (semaglutide) vs +0.6% (placebo); estimated treatment difference -16.7 percentage points (p<0.001) |

The Clinical Effect That Economists Are Pricing

Before dissecting economic models, the clinical signal matters. STEP-TEENS randomized 201 adolescents (2:1 semaglutide-to-placebo) and reported a BMI reduction of 16.1% at 68 weeks in the treatment arm. 73% of semaglutide-treated participants achieved ≥5% weight loss compared with 18% on placebo. These effect sizes are comparable to what was observed in the adult STEP 1 trial, which formed the basis of Wegovy's FDA approval for chronic weight management in patients aged 12 and older.

The question that follows the efficacy data is always the same: at what price does that benefit justify the expenditure, and who ends up paying?

List Price vs. Net Price: The Gap That Distorts Every Calculation

Wegovy's wholesale acquisition cost (WAC) sits near $1,350 per month, or roughly $16,200 annually. This is the figure most media coverage cites and the number that drives sticker-shock reactions from families. But WAC is not what payers actually remit after rebates, discounts, and negotiated pricing.

The table below presents a framework for understanding how price tiers affect cost-effectiveness conclusions for adolescent semaglutide use based on STEP-TEENS outcomes.

| Price Scenario | Annual Drug Cost (est.) | 3-Year Treatment Cost | ICER Context (per QALY, lifetime horizon) | |---|---|---|---| | WAC (list) | ~$16,200 | ~$48,600 | Exceeds $150,000/QALY in most published models | | Estimated net (post-rebate) | ~$8,000-$11,000 | ~$24,000-$33,000 | Approaches $100,000-$130,000/QALY range | | Patient out-of-pocket (insured, preferred formulary) | $0-$1,500/yr | $0-$4,500 | Not directly comparable to ICER but drives adherence | | Patient out-of-pocket (no coverage) | ~$16,200 | ~$48,600 | Prohibitive for most families without manufacturer savings programs |

Net prices for GLP-1 receptor agonists have been estimated at 40-50% below WAC in some analyses, though exact figures remain proprietary. ICER's 2022 assessment of anti-obesity medications in adults found semaglutide 2.4 mg exceeded commonly cited willingness-to-pay thresholds at list price but moved closer to value-based benchmarks when net-price assumptions were applied. No adolescent-specific ICER review has been published as of 2026, which means all pediatric cost-effectiveness estimates are extrapolated from adult data or built on modeled assumptions about adolescent QALY gains.

How Cost-Effectiveness Models Handle Adolescents Differently

Modeling obesity treatment value in a 14-year-old is fundamentally different from modeling it in a 50-year-old. Three factors change the math.

Longer time horizon. A treatment initiated at age 14 has 50+ years of potential health-outcome impact. This favors the intervention in lifetime models because averted type 2 diabetes, cardiovascular events, and joint disease accumulate over decades. Adult models typically use 30- to 40-year horizons.

Uncertainty in weight regain. STEP-TEENS extension data and the broader STEP program show weight regain after treatment discontinuation. If an adolescent uses semaglutide for 68 weeks and then stops, a large share of weight returns within 1 to 2 years. Models that assume continuous treatment generate very different ICERs from models that assume a defined treatment course. A 3-year treatment period at net price produces a more favorable ICER than lifetime continuous dosing, but the clinical durability assumption behind a 3-year course remains unvalidated in prospective data.

QALY estimation in pediatric populations. Quality-adjusted life years in adolescents incorporate different utility weights. Obesity-related disutility in teens includes psychosocial burden (bullying, depression, social withdrawal) that may not map neatly onto adult health-utility instruments like the EQ-5D. Some models have used the PedsQL obesity module to generate utility inputs, but these are not yet standardized across published analyses.

Published and Modeled Cost-Effectiveness Estimates

Direct cost-effectiveness analyses of semaglutide 2.4 mg using STEP-TEENS efficacy inputs remain limited. The available evidence can be grouped into three categories.

Manufacturer-sponsored modeling. Novo Nordisk-funded analyses have presented semaglutide as cost-effective at net price under lifetime horizons, particularly when incorporating averted comorbidity costs. These models assume sustained treatment effect and use optimistic adherence projections.

Independent academic models. Several groups have adapted adult STEP 1-based models to adolescent populations by substituting STEP-TEENS BMI reduction inputs. These tend to produce ICERs between $100,000 and $200,000 per QALY at list price with 10-year treatment durations. At net price with 3-year treatment courses, some models report ICERs below $100,000 per QALY, a threshold frequently cited in U.S. value assessments.

ICER and HTA body assessments. ICER reviewed anti-obesity medications broadly in 2022 and found that semaglutide 2.4 mg for adults did not meet value-based price benchmarks at WAC. The review recommended price discounts of 40-60% to achieve thresholds of $100,000-$150,000 per QALY. No adolescent-specific review has been issued. European HTA bodies, including NICE, have not published pediatric obesity pharmacotherapy technology appraisals for semaglutide as of mid-2026.

Payer Coverage: A Fragmented Picture

Coverage for Wegovy in adolescents varies dramatically by plan type, state, and employer.

Commercial plans. Large employer-sponsored plans increasingly cover GLP-1 agonists for adult obesity, but adolescent coverage often requires prior authorization with documentation of failed lifestyle intervention, BMI thresholds, and comorbidity presence. Step therapy requirements (trying other agents first) are common. Some plans exclude anti-obesity medications entirely, a policy inherited from an era when pharmacotherapy options were limited to phentermine and orlistat.

Medicaid. State Medicaid programs show the widest variation. Some states cover Wegovy for beneficiaries under 18 with appropriate diagnoses. Others classify anti-obesity medications as optional or excluded. The Inflation Reduction Act provisions related to Medicare drug negotiation do not directly affect Medicaid adolescent formularies, but political pressure around GLP-1 spending is prompting formulary reviews across state programs.

Patient assistance. Novo Nordisk offers savings cards that reduce out-of-pocket costs for commercially insured patients, typically capping copays at $25-$150 per month. Uninsured patients may qualify for the patient assistance program, but eligibility criteria and supply constraints have limited uptake.

The practical result: two adolescents with identical clinical profiles in the same city may have completely different access depending on their parent's employer, insurance tier, and state of residence.

What "Cost-Effective" Means for Individual Families

Population-level ICERs do not answer the question a parent asks in a pediatric endocrinology clinic: "Is this worth it for my child?"

Individual value depends on several factors that cost-effectiveness models average across populations.

Severity of obesity and comorbidity burden. An adolescent with a BMI of 42, prediabetes, and obstructive sleep apnea stands to gain more health utility per dollar than a teen with a BMI of 32 and no comorbidities. The STEP-TEENS subgroup analyses showed consistent treatment effects across baseline BMI categories, but absolute clinical benefit (comorbidity resolution) correlates with severity.

Alternative treatment options. For adolescents who have not responded to structured lifestyle programs and are not candidates for or decline metabolic surgery, pharmacotherapy may represent the only remaining intervention with demonstrated efficacy of this magnitude. The AAP Clinical Practice Guidelines for pediatric obesity (2023) recommend pharmacotherapy for adolescents aged 12+ with obesity, positioning drugs like semaglutide as a guideline-supported option rather than a last resort.

Duration of intended use. Families planning a 1-year trial of semaglutide face a $16,200 WAC decision (less with insurance). Those anticipating chronic, indefinite use face a multi-year commitment with uncertain long-term cost trajectories as biosimilars and competing agents enter the market.

Psychosocial return. Some families report improvements in school attendance, social engagement, and mental health that are difficult to capture in standard QALY calculations but represent substantial value to the adolescent and household. These outcomes were not primary or secondary endpoints in STEP-TEENS and remain unstudied in formal health-economic terms.

Limitations of Current Economic Evidence

The health-economic evidence base for semaglutide in adolescents has significant gaps.

First, no completed prospective cost-effectiveness study has used STEP-TEENS as its primary efficacy source alongside real-world cost and utilization data. All published ICERs rely on modeled assumptions. Second, weight regain after discontinuation has not been incorporated into most published models with adolescent-specific trajectories. Adult regain data from STEP 1 extensions may underestimate or overestimate the problem in younger patients. Third, the comparator in economic models is typically lifestyle intervention alone, but in clinical practice, some adolescents are offered orlistat, phentermine (off-label), or metabolic surgery. Head-to-head economic comparisons against these alternatives are absent. Finally, most models use a U.S. healthcare-cost perspective. The value proposition differs substantially in single-payer systems where drug pricing mechanisms, comorbidity management costs, and willingness-to-pay thresholds diverge from U.S. benchmarks.

The Biosimilar and Competition Horizon

The economic calculus will shift as the competitive market evolves. Tirzepatide (Zepbound) gained FDA approval for chronic weight management in adults and is being studied in adolescents. Oral semaglutide at higher doses and next-generation GLP-1/GIP/glucagon triple agonists are in late-stage trials. If these agents demonstrate comparable or superior efficacy in teens, price competition could reduce per-patient costs.

Semaglutide's patent protections extend into the early 2030s, meaning biosimilar entry for the injectable formulation is years away. In the interim, the economic argument for semaglutide in adolescents will rest on negotiated net pricing, payer willingness to cover pediatric indications, and accumulating real-world evidence on long-term outcomes that validate the modeled QALY gains.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Weghuber D, Barrett T, Engberg S, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245-2257. PubMed
2. FDA. Wegovy (semaglutide) injection prescribing information. Revised 2023. FDA Label
3. Institute for Clinical and Economic Review. Anti-obesity medications: effectiveness and value. 2022. PubMed
4. Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640. PubMed
5. Inflation Reduction Act of 2022 (H.R. 5376). 117th Congress. Congress.gov